Guggenheim Capital’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-26,426
| Closed | -$523K | – | 2159 |
|
|
2020
Q4 | $523K | Sell |
26,426
-93,062
| -78% | -$1.5M | ﹤0.01% | 1618 |
|
|
2020
Q3 | $1.56M | Sell |
119,488
-16,054
| -12% | -$203K | 0.01% | 1001 |
|
|
2020
Q2 | $1.54M | Buy |
135,542
+38,852
| +40% | +$552K | 0.01% | 995 |
|
|
2020
Q1 | $1.38M | Sell |
96,690
-17,762
| -16% | -$375K | 0.01% | 945 |
|
|
2019
Q4 | $3.12M | Buy |
114,452
+8,780
| +8% | +$242K | 0.02% | 851 |
|
|
2019
Q3 | $3.03M | Sell |
105,672
-12,768
| -11% | -$372K | 0.02% | 839 |
|
|
2019
Q2 | $3.29M | Buy |
118,440
+16,807
| +17% | +$475K | 0.03% | 814 |
|
|
2019
Q1 | $3.38M | Sell |
101,633
-97,526
| -49% | -$2.97M | 0.03% | 823 |
|
|
2018
Q4 | $5.79M | Sell |
199,159
-2,637
| -1% | -$94.9K | 0.05% | 491 |
|
|
2018
Q3 | $9.28M | Sell |
201,796
-119,080
| -37% | -$5.29M | 0.06% | 376 |
|
|
2018
Q2 | $12M | Sell |
320,876
-46,093
| -13% | -$1.56M | 0.08% | 275 |
|
|
2018
Q1 | $10.8M | Sell |
366,969
-5,134
| -1% | -$174K | 0.03% | 653 |
|
|
2017
Q4 | $12.8M | Sell |
372,103
-30,773
| -8% | -$1.04M | 0.03% | 617 |
|
|
2017
Q3 | $14.6M | Buy |
402,876
+203,323
| +102% | +$5.8M | 0.03% | 572 |
|
|
2017
Q2 | $5.16M | Sell |
199,553
-13,491
| -6% | -$286K | 0.01% | 1001 |
|
|
2017
Q1 | $4.09M | Buy |
213,044
+60,418
| +40% | +$1.07M | 0.01% | 1148 |
|
|
2016
Q4 | $2.54M | Sell |
152,626
-13,420
| -8% | -$243K | 0.01% | 1486 |
|
|
2016
Q3 | $3.42M | Buy |
166,046
+4,609
| +3% | +$117K | 0.01% | 1250 |
|
|
2016
Q2 | $4.94M | Buy |
161,437
+6,124
| +4% | +$213K | 0.02% | 1006 |
|
|
2016
Q1 | $5.81M | Sell |
155,313
-61,640
| -28% | -$2.32M | 0.02% | 913 |
|
|
2015
Q4 | $9.36M | Sell |
216,953
-55,751
| -20% | -$2.36M | 0.03% | 770 |
|
|
2015
Q3 | $10.2M | Sell |
272,704
-95,861
| -26% | -$3.4M | 0.03% | 737 |
|
|
2015
Q2 | $12.5M | Buy |
368,565
+21,181
| +6% | +$720K | 0.03% | 753 |
|
|
2015
Q1 | $12.3M | Buy |
347,384
+48,011
| +16% | +$1.72M | 0.03% | 774 |
|
|
2014
Q4 | $10.2M | Sell |
299,373
-46,132
| -13% | -$1.64M | 0.03% | 828 |
|
|
2014
Q3 | $13.3M | Buy |
345,505
+19,107
| +6% | +$713K | 0.03% | 783 |
|
|
2014
Q2 | $12.7M | Buy |
326,398
+53,056
| +19% | +$1.97M | 0.03% | 784 |
|
|
2014
Q1 | $9.35M | Sell |
273,342
-6,374
| -2% | -$197K | 0.03% | 874 |
|
|
2013
Q4 | $5.87M | Buy |
279,716
+28,011
| +11% | +$708K | 0.02% | 1021 |
|
|
2013
Q3 | $5.92M | Buy |
251,705
+55,277
| +28% | +$1.57M | 0.02% | 1023 |
|
|
2013
Q2 | $5.28M | Buy |
+196,428
| New | +$5.69M | 0.02% | 1027 |
|
Other funds holding MYGN
CCM
PHS
GCM
Guggenheim Capital's MYGN Position: Q1 2021 in Review
Guggenheim Capital sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 26,426 shares — an estimated $523K sold.
Guggenheim Capital first reported a position in MYGN in Q2 2013 and held it in 31 quarters. The position peaked at $14.6M in Q3 2017. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.
- Guggenheim Capital reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
- Guggenheim Capital sold 26,426 Myriad Genetics shares in Q1 2021, an estimated $523K.
- Guggenheim Capital first reported a position in Myriad Genetics in Q2 2013 and held it in 31 quarters.
- Guggenheim Capital's Myriad Genetics position peaked at $14.6M in Q3 2017.
- 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.
Based on Guggenheim Capital's 13F filing for Q1 2021, filed 13 May 2021.